excretion data (unclear) Providers: not blinded Outcome assessors: unclear Summary table Citation Study Population Intervention Outcomes Sample size Intervention Compliance to Results & design level measured duration sodium target location of relevant to (urinary data) research question Singer et II Adults with Whilst remaining on SBP, DBP, 21 4 weeks per 24 hour urinary Comparison MAP al (1991), essential medications (and treatment sodium excretion: between UK cross hypertension following 1 run change in Low over (mean age in phase of usual diet), placebo and [] placebo 53±2.5 participants were high sodium treatment: taking captopril instructed by a treatments (50mg twice dietitian to reduce (supine BP): daily) and dietary sodium (aim High sodium SBP: -9mmHg 80-100mmol/day) for treatment: (SEM: 3, 95%CI: cross (diuretic) two weeks prior to -14.88, -3.12) 25mg/day for at least a
excretion data (unclear) Providers: not blinded Outcome assessors: unclear Summary table Citation & location Study design level of Population Intervention Outcomes measured relevant to research question Sample size Intervention duration Compliance to sodium target (urinary data) Results Singer et al (1991), UK [] cross over placebo cross II Adults with essential hypertension (mean age 53±2.5 taking captopril (50mg twice daily) and (diuretic) 25mg/day for at least a Whilst remaining on medications (and following 1 run in phase of usual diet), participants were instructed by a dietitian to reduce dietary sodium (aim 80-100mmol/day) for two weeks prior to SBP, DBP, MAP 21 4 weeks per treatment 24 hour urinary sodium excretion: Low treatment: High sodium treatment: Comparison between change in placebo and high sodium treatments (supine BP): SBP: -9mmHg (SEM: 3, 95%CI: -14.88, -3.12)
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx